Network meta-analyses and treatment recommendations for obsessive-compulsive disorder – Authors' reply by Skapinakis, P et al.
 1 
Skapinakis P*, Caldwell DM, Hollingworth W, Welton NJ, Fineberg N, Salkovskis P, 
Churchill R, Lewis G. Network meta-analyses and treatment recommendations 
for obsessive-compulsive disorder - Authors' reply.  Lancet Psychiatry 2016 
Oct; 3(10): 921-922.  doi:10.1016/S2215-0366(16)30282-6. 
 
Affiliations: Department of Psychiatry, University of Ioannina School of 
Medicine, Greece (PSk); Division of Psychiatry, University College London, UK 
(PSk, GL); School of Social and Community Medicine, University of Bristol, UK 
(DC, WH, NW); University of Hertfordshire and Hertfordshire Partnerships 
Mental Health Trust, Hatfield, UK (NF); Department of Psychology, University of 
Bath, UK (PSal); Centre for Reviews and Dissemination, University of York, UK 
(RC). 
*p.skapinakis@gmail.com 
 
We agree with Tan Shian Ming  that concomitant use of medications in 
psychotherapy trials is a problem for interpreting the treatment effects of 
psychotherapy in OCD. Concurrent medications used in these trials are not just 
antidepressant but specifically anti-obsessive drugs. In our network meta-
analysis, based on the existing study data, we cannot be sure to what extent we 
are evaluating outcomes on psychotherapy as monotherapy or psychotherapy 
combined with medication.  
Tan Shian Ming’s second point is that the transitivity assumption of our 
network meta-analysis may not hold because the proportion of patients with 
concomitant use of medications differed among psychotherapy trials. We were 
very careful in assessing the methodological assumptions of the network meta-
analysis, including the transitivity assumption and assessment of statistical 
inconsistency between direct and indirect evidence.1 For the transitivity 
assumption, we considered several potential effect modifiers, such as baseline 
symptom severity, age, length of trial follow-up, proportion of participants with 
depression, and year of publication, but there was no evidence that the 
assumption of transitivity did not hold across the trials and comparisons.1 
Proportion of patients with concomitant use of medications in psychotherapy 
trials was not considered at the protocol stage as this was not reported in 
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previous meta-analyses in the field. Only two studies reported that they excluded 
such patients and for a third it was unclear. In our second sensitivity analysis 
(“incomplete outcome assessment”), we excluded these three studies and the 
results were not different from the main analysis. Therefore, we think it is 
unlikely that this aspect of the study threatens the (internal) validity of our 
results. Finally, we are aware of the several techniques used in variants of 
cognitive behavioral treatment for OCD; all trials in our review used techniques 
specific to OCD but the more detailed assessment of these specific interventions 
was beyond the scope of the current review. Future research focusing only in 
psychotherapy trials may be more suitable for such comparisons. 
   Michael Wheaton and colleagues argue that our data “do not clearly 
demonstrate superiority of combination treatment”. We agree and reported that 
“psychotherapeutic interventions had a greater effect than did medications”. 
Interpretation of these results, however, should take into account both internal 
and external validity (generalisability)2. Regarding internal validity Wheaton and 
colleagues note that “direct comparisons offer a higher level of evidence”. 
However, in cases where there are both direct and indirect evidence, ignoring 
the indirect part will result in reduced precision and less confidence3. Leucht and 
colleagues3 argue that network meta-analyses should be now considered as the 
highest level of evidence. Regarding external validity, since most 
psychotherapeutic studies did not exclude patients on medications, it is not 
appropriate to generalise findings to patients not taking such medications. Even 
though patients were symptomatic at trial recruitment, there is no information 
on the pre-randomization / pre-medication period, including the severity and 
course of both the obsessive-compulsive symptoms and comorbid depression. 
Abramowitz et al.4 have shown that the relationship between depressive 
symptoms and response to psychotherapy in OCD is non-linear. In their 
pragmatic cohort of OCD patients, treatment response for behavioural therapy 
differed according to depression severity, being 100% in the non-depressed 
patients versus 0% in the severely depressed.4 These patients are usually 
excluded from RCTs, but it is likely that prior treatment with antidepressants 
reduced the levels of depression and thus contributed to the subsequent good 
effect of psychotherapies in such trials.  
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Patients included in the reviewed RCTs had long-standing and severe 
OCD. This is typical in treated samples: in a long-term follow-up study (10-20 
years), half the cohort still had symptoms that would make them eligible for 
inclusion in a new trial, while 70% were receiving medication at follow-up and 
50% had received behavioural or cognitive-behavioural therapy at some point in 
their lives.5 First-line treatment decisions will require trials with treatment-naïve 
patients or patients with shorter duration of illness, but given the available 
evidence, we believe that our interpretation better reflects what happens in 
everyday clinical practice.          
 
We declare no competing interests 
 
References 
1. Skapinakis P, Caldwell D, Hollingworth W, et al. A systematic review of the 
clinical effectiveness and cost-effectiveness of pharmacological and 
psychological interventions for the management of obsessive-compulsive 
disorder in children/adolescents and adults. Health Technol Assess 2016; 20:1-
392. 
2. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for 
reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 
134:663-694. 
3. Leucht S, Chaimani A, Cipriani AS, et al. Network meta-analyses should be the 
highest level of evidence in treatment guidelines. Eur Arch Psychiatry Clin 
Neurosci 2016; 266:477-480. 
4. Abramowitz JS, Franklin ME, Street GP, et al. Effects of comorbid depression on 
response to treatment for obsessive-compulsive disorder. Behav Ther 2000; 
31:517–528. 
5. Bloch MH, Green C, Kichuk SA, et al. Long-term outcome in adults with 
obsessive-compulsive disorder. Depress Anxiety 2013; 30:716–22.  
 
